Comparison of observed and predicted renal clearance values (ml/min per kg or *log ml/min per kg) of compounds with overlapping substrate/inhibitor specificity for the renal transporters
| Compound | Observed | OAT1/3 | MRP2/4 | P-gp | OCT2 | MATE1/2K |
|---|---|---|---|---|---|---|
| Acyclovir | 3.57 | 5.14 | — | — | — | 4.21 |
| Adefovir | 3.33 | 2.81 | 3.60 | — | — | — |
| Cephalexin | 3.54, 0.55* | — | — | — | 0.68* | 4.13 |
| Chloroquine | 2.29, 0.36* | — | — | — | 0.07* | 1.99 |
| Cimetidine | 7.90, 0.89* | 6.80 | — | — | 0.50* | 6.46 |
| Ciprofloxacin | 6.90 | 6.53 | 5.23 | — | — | — |
| Cyclosporine | 0.08, -1.12* | — | 0.28 | −1.21* | — | — |
| Dofetilide | 3.12, 0.49* | — | — | — | 0.45* | 1.79 |
| Famotidine | 4.42, 0.64* | 4.25 | — | — | 0.67* | 6.07 |
| Furosemide | 1.70 | 1.24 | 0.84 | — | — | — |
| Ganciclovir | 4.14 | 3.36 | — | — | — | 3.54 |
| Imipramine | 0.26, -0.58* | — | — | — | −0.67* | 0.38 |
| Irinotecan | 2.24, 0.35* | — | 2.16 | 0.37* | — | — |
| Metformin | 7.40, 0.86* | — | — | — | 0.94* | 5.81 |
| Methotrexate | 1.70 | 1.39 | 2.78 | — | — | 1.46 |
| Pindolol | 3.90, 0.59* | — | — | — | 0.47* | 4.83 |
| Procainamide | 4.50, 0.65* | — | — | — | 0.61* | 4.63 |
| Quinidine | −0.22* | — | — | −0.12* | −0.17* | — |
| Ranitidine | 7.40, 0.86* | — | — | — | 0.90* | 7.15 |
| Tenofovir | 2.70 | 4.76 | 3.83 | — | — | — |
| Topotecan | 5.20, 0.71* | — | 5.16 | 0.54* | — | 4.99 |
| Verapamil | 0.54, -0.27* | — | — | −0.37* | −0.18* | 0.58 |
| Vinblastine | 2.63, 0.42* | — | 3.10 | 0.43* | — | — |
| Zidovudine | 5.67, 0.75* | 5.16 | — | — | 0.62 | — |
↵* Log CLR values, as predicted for P-gp and OCT2 subsets.